EPIDEMIOLOGY AND DIAGNOSTIC TOOLS TO DETECT AND DIAGNOSE PROSTATE CANCER
DOI:
https://doi.org/10.47413/wggk3t17Abstract
One of the cancers that affects men and has a major impact on the rising death rates among men worldwide is prostate cancer. Prostate cancer patients may have localized or advanced disease at presentation. Our goal in this study is to present a comprehensive picture of prostate cancer, covering its epidemiology and several diagnostic techniques.
Prostate-specific antigen (PSA) testing, transrectal ultrasound (TRUS), magnetic resonance imaging (MRI), prostate biopsy, Positron emission tomography (PET) scan, risk stratification bioassay test, germline testing, digital rectal exam (DRE), and single-cell RNA-sequencing (scRNA-seq) were among the techniques we covered. For clinical and patient care, prostate cancer (PCa) diagnosis and appropriate staging are essential. Thanks to extensive medical research and development, sensitive and advanced diagnostic instruments are now available. Prostate-specific antigen (PSA) blood testing and rectal examination continue to be the mainstays of screening, while multiparametric magnetic resonance imaging (mpMRI) is used for local staging. In order to better detect clinically significant PCa and identify patients who need targeted biopsies, recent developments in mpMRI, PET, and MRI have led to standardized interpretation and greater prescription by doctors. Other types that are becoming increasingly important, particularly to identify the recurrent rate of cancer, include germline testing, risk stratification bioassay testing, and single-cell RNA-sequencing (scRNA-seq). The combined use of these technologies will assist patients and clinicians in selecting the most suitable and individualized course of treatment for this highly variable condition and also make early diagnosis achievable.
References
1. Abida W, Cheng ML, Armenia J, et al: Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol 5:471-478, 2019.
2. Abida W, Patnaik A, Campbell D, et al: Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 38:3763-3772, 2020.
3. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–22.
4. Anon., 2013a. Three Year Report of Population Based Cancer Registries 2009–2011. National Cancer Registry Programme, Indian Council of Medical Research, Bangalore, India (Feb, Available from: http://www.ncrpindia.org/ALL_NCRP_REPORTS/PBCR_REPORT_2009_2011/index.htm).
5. Barrett, T.; de Rooij, M.; Giganti, F.; Allen, C.; Barentsz, J.O.; Padhani, A.R. Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway. Nat. Rev. Urol. 2023, 20, 9–22.
6. Beheshti M, Rezaee A, Geinitz H, Loidl W, Pirich C, Langsteger W. Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT. J Nucl Med. 2016 Oct;57(Suppl 3):55S-60S. doi: 10.2967/jnumed.115.169730. PMID: 27694173.
7. Bell N, Connor Gorber S, Shane A, Joffres M, Singh H, Dickinson J, et al. (November 2014). "Recommendations on screening for prostate cancer with the prostate-specific antigen test". CMAJ. 186 (16): 1225–34.
8. Bell, K.J., et al. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer, 2015. 137: 1749.
9. Bhargavi R, Khilwani B, Kour B, Shukla N, Aradhya R, Sharma D, et al. Prostate cancer in India: Current perspectives and the way forward. J Reprod Healthc Med 2023;4:8.
10. Boehm, B.E.; York, M.E.; Petrovics, G.; Kohaar, I.; Chesnut, G.T. Biomarkers of Aggressive Prostate Cancer at Diagnosis. Int. J. Mol. Sci. 2023, 24, 2185.
11. Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ (May–June 2011). "Advancements in MR imaging of the prostate: from diagnosis to interventions". Radiographics. 31 (3): 677 703. doi:10.1148/rg.313105139. PMC 3093638. PMID 21571651.
12. Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R, et al. Lyon: International Agency for Research on Cancer Scientific Publications; 2017. Cancer incidence in five continents volume XI. [Google Scholar]
13. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
14. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424.
15. Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645–53. doi: 10.1158/1078-0432.CCR-11-1357.
16. Cornford P, van den Bergh RCN, Briers E, et al: EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer. Eur Urol 79:263-282, 2021
17. Culp, M.B., et al. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol, 2020. 77: 38.
18. Debora Z. Recchimuzzi, MD • Alberto Diaz de Leon, MD • Ivan Pedrosa, MD, PhD • Debbie Travalini, PAC • Heather Latin, RT • Kenneth Goldberg, MD Xiaosong Meng, MD, PhD • Jovan Begovic, MD • Jesse Rayan, MD • Claus G. Roehrborn, MD • Neil M. Rofsky, MD • Daniel N. Costa, MD. Direct MRI-guided In-Bore Targeted Biopsy of the Prostate: A Step-by-Step How To and Lessons Learned. RadioGraphics 2024; 44(2):e230142
19. Fernandes MC, Yildirim O, Woo S, Vargas HA, Hricak H. The role of MRI in prostate cancer: current and future directions. MAGMA. 2022 Aug;35(4):503-521. doi: 10.1007/s10334-022-01006-6. Epub 2022 Mar 16. PMID: 35294642; PMCID: PMC9378354.
20. Fleshner, K., et al. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol, 2017. 14: 26.
21. Gao T, Zhao S, Sun J, Huang Q, Long S, Lv M, et al. Single-cell quantitative phenotyping via the aptamer-mounted nest-PCR (Apt-nPCR). Anal Chem. 2022;94(5):2383–90.
22. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:301–9.
23. Glazer DI, Davenport MS, Khalatbari S, Cohan RH, Ellis JH, Caoili EM, et al. Mass-like peripheral zone enhancement on CT is predictive of higher-grade (Gleason 4 + 3 and higher) prostate cancer. Abdom Imaging. 2015;40(3):560–70.
24. Gunes S, Hekim GN, Arslan MA, Asci R. Effects of aging on the male reproductive system. J Assist Reprod Genet. 2016 Apr;33(4):441-54.
25. Guo, J.; Liu, D.; Zhang, X.; Johnson, H.; Feng, X.; Zhang, H.; Wu, A.H.B.; Chen, L.; Fang, J.; Xiao, Z.; et al. Establishing a Urine-Based Biomarker Assay for Prostate Cancer Risk Stratification. Front. Cell. Dev. Biol. 2020, 8, 597961.
26. Gupta A, Shukla N, Nehra M, Gupta S, Malik B, Mishra AK, et al. A pilot study on the whole exome sequencing of prostate cancer in the Indian phenotype reveals distinct polymorphisms. Front Genet. 2020;11:874.
27. Haas, G.P., et al. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol, 2008. 15: 3866.
28. Harvey CJ, Pilcher J, Richenberg J, Patel U, Frauscher F. Applications of transrectal ultrasound in prostate cancer. Br J Radiol. 2012 Nov;85 Spec No 1(Spec Iss 1):S3-17. doi: 10.1259/bjr/56357549. Epub 2012 Jul 27. PMID: 22844031; PMCID: PMC3746408.
29. Haupt F, Dijkstra L, Alberts I. 68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer-a modified protocol compared with the common protocol. Eur J Nucl Med Mol Imaging. 2020;47:624–31. doi: 10.1007/s00259-019-04548-5.
30. Hussain M, Mateo J, Fizazi K, et al: Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 383:2345-2357, 2020.
31. IARC. IARC France All Cancers (excluding non-melanoma skin cancer) Estimated Incidence, Mortality and Prevalence Worldwide in 2012. 2014.
32. Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. (September 2018). "Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis". BMJ. 362: k3519.
33. Isebaert S, Van den Bergh L, Haustermans K, Joniau S, Lerut E, De Wever L, et al. (June 2013). "Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology". Journal of Magnetic Resonance Imaging. 37 (6): 1392–401. doi:10.1002/jmri.23938. PMID 23172614.
34. Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013;40:S5–10.
35. Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013;40:S5–10.
36. Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, et al. Inference and analysis of cell-cell communication using cell chat. Nat Commun. 2021;12(1):1088.
37. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. The New England journal of medicine. 2018;378(19):1767–77.
38. Kitajima K, Murphy RC, Nathan MA. Choline PET/CT for imaging prostate cancer: an update. Ann Nucl Med. 2013 Aug;27(7):581-91. doi: 10.1007/s12149-013-0731-7. Epub 2013 Apr 30. PMID: 23632880.
39. Klotz L. Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes. 2013 Jun;20(3):204-9.
40. Krilaviciute A, Becker N, Lakes J, Radtke JP, Kuczyk M, Peters I, Harke NN, Debus J, Koerber SA, Herkommer K, Gschwend JE, Meissner VH, Benner A, Seibold P, Kristiansen G, Hadaschik B, Arsov C, Schimmöller L, Giesel FL, Antoch G, Makowski M, Wacker F, Schlemmer HP, Kaaks R, Albers P. Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer. Eur Urol Oncol. 2023 Dec;6(6):566-573. doi: 10.1016/j.euo.2023.09.008. Epub 2023 Oct 6. PMID: 37806841.
41. Kwon DH, Gordon KM, Tong B, et al: Implementation of a telehealth genetic testing station to deliver germline testing for men with prostate cancer. JCO Oncol Pract 19:e773-e783, 2023.
42. Kwon DH, Velazquez AI, de Kouchkovsky I. PSMA PET Scan. JAMA Oncol. 2022;8(12):1860. doi:10.1001/jamaoncol.2022.3531
43. Lalitha K, Suman G, Pruthvish S, Mathew A, Murthy NS. Estimation of time trends of incidence of prostate cancer-an Indian scenario. Asian Pac J Cancer Prev. 2012;13:6245-50.
44. Leal J, Welton NJ, Martin RM, Donovan J, Hamdy F, Neal D, Noble S, Lane A, Wolstenholme J. Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. Cancer Epidemiol. 2018 Feb;52:99-105. [PubMed]
45. Lebastchi AH, Russell CM, Niknafs YS, Eyrich NW, Chopra Z, Botbyl R, Kabeer R, Osawa T, Siddiqui J, Siddiqui R, Davenport MS, Mehra R, Tomlins SA, Kunju LP, Chinnaiyan AM, Wei JT, Tosoian JJ, Morgan TM. Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice. Urology. 2020 Nov;145:204-210.
46. Liu, Chengbo & Xing, Muyue & Cong, Bing & Qiu, Chen & He, Dong & Wang, Congzhi & Xiao, Yang & Yin, Tinghui & Shao, Min & Qiu, Weibao & Ma, Teng & Gong, Xiaojing & Chen, Xiong & Zheng, Hairong & Zheng, Rongqin & Song, Liang. (2019). In vivo transrectal imaging of canine prostate with a sensitive and compact handheld transrectal array photoacoustic probe for early diagnosis of prostate cancer. Biomedical Optics Express. 10. 1707. 10.1364/BOE.10.001707.
47. Marks L, Young S, Natarajan S (January 2013). "MRI-ultrasound fusion for guidance of targeted prostate biopsy". Current Opinion in Urology. 23 (1): 43–50. doi:10.1097/MOU.0b013e32835ad3ee. PMC 3581822. PMID 23138468.
48. Marron-Esquivel, J.M.; Duran-Lopez, L.; Linares-Barranco, A.; Dominguez-Morales, J.P. A comparative study of the inter-observer variability on Gleason grading against Deep Learning-based approaches for prostate cancer. Comput. Biol. Med. 2023, 159, 106856.
49. Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, et al. Cancer statistics, 2020:Report from National Cancer Registry Programme, India. JCO Glob Oncol. 2020;6:1063–75. doi: 10.1200/GO.20.00122.
50. Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, et al. Cancer statistics, 2020: Report from national cancer registry program, India. JCO Glob Oncol. 2020;6:1063-75.
51. Maurer T, Eiber M, Schwaiger M, et al. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13:226–35. doi: 10.1038/nrurol.2016.26.
52. Meller BF, Bremmer CO, Sahlmann S, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5:66. doi: 10.1186/s13550-015-0145-8.
53. Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Fütterer JJ, Gill IS, et al. (October 2013). "Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group". European Urology. 64 (4): 544–52.
54. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: The saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310-20.
55. O' Donoghue PM, McSweeney SE, Jhaveri K (2010). "Genitourinary imaging: current and emerging applications". J Postgrad Med. 56 (2): 131–9. doi:10.4103/0022-3859.65291
56. Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, Concepcion R, David RD, Deck KB, Dumbadze I, Gambla M, Grable MS, Henderson RJ, Karsh L, Krisch EB, Langford TD, Lin DW, McGee SM, Munoz JJ, Pieczonka CM, Rieger-Christ K, Saltzstein DR, Scott JW, Shore ND, Sieber PR, Waldmann TM, Wolk FN, Zappala SM. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015 Sep;68(3):464-70.
57. Patel AR, Jones JS (May 2009). "Optimal biopsy strategies for the diagnosis and staging of prostate cancer". Current Opinion in Urology. 19 (3): 232–7.
58. Pokorny MR, de Rooij M, Duncan E, Schröder FH, Parkinson R, Barentsz JO, Thompson LC (July 2014). "Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies". European Urology. 66 (1): 22–9.
59. Rais-Bahrami, S., Efstathiou, J.A., Turnbull, C.M. et al. 18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review. Prostate Cancer Prostatic Dis 24, 997–1006 (2021). https://doi.org/10.1038/s41391-021-00382-9
60. Raja J, Ramachandran N, Munneke G, Patel U. Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Clin Radiol 2006;61:142–53.
61. Rastrelli G, Corona G, Vignozzi L, Maseroli E, Silverii A, Monami M, et al. Serum PSA as a predictor of testosterone deficiency. J Sex Med. 2013;10:2518-28.
62. Rebello, R.J.; Oing, C.; Knudsen, K.E.; Loeb, S.; Johnson, D.C.; Reiter, R.E.; Gillessen, S.; Van der Kwast, T.; Bristow, R.G. Prostate cancer. Nat. Rev. Dis. Primers 2021, 7, 9. Berish, R.B.; Ali, A.N.; Telmer, P.G.; Ronald, J.A.; Leong, H.S. Translational models of prostate cancer bone metastasis. Nat. Rev. Urol. 2018, 15, 403–421. Ritch, C.R.; Cookson, M.S. Advances in the management of castration resistant prostate cancer. BMJ 2016, 355, i4405. [Google Scholar] [CrossRef] [Green Version]
63. Roberts MJ, Bennett HY, Harris PN, Holmes M, Grummet J, Naber K, Wagenlehner FM (June 2017). "Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches" (PDF). Urology. 104: 11–21.
64. Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ. Prostatitis as a risk factor for prostate cancer. Epidemiol. 2004;15:93-9.
65. Russo J, Giri VN: Germline testing and genetic counselling in prostate cancer. Nat Rev Urol 19:331-343, 2022
66. Sandhu, S.; Moore, C.M.; Chiong, E.; Beltran, H.; Bristow, R.G.; Williams, S.G. Prostate cancer. Lancet 2021, 398, 1075–1090.
67. Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India. Indian J Med Res. 2022 Oct-Nov;156(4&5):598-607. doi: 10.4103/ijmr.ijmr_1821_22. PMID: 36510887; PMCID: PMC10231735.
68. Seetharam Bhat KR, Samavedi S, Moschovas MC, Onol FF, Roof S, Rogers T, et al. Magnetic resonance imaging-guided prostate biopsy-A review of literature. Asian J Urol. 2021;8(1):105–16.
69. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. doi: 10.3322/caac.21708. [DOI] [PubMed] [Google Scholar]
70. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 2018, 68, 7–30.
71. Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 2023, 73, 17–48.
72. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. doi: 10.3322/caac.21660.
73. Taha DE, Aboumarzouk OM, Koraiem IO, Shokeir AA. Antibiotic therapy in patients with high prostate-specific antigen: Is it worth considering? A systematic review. Arab J Urol. 2020;18(1):1-8.
74. Taira AV, Merrick GS, Galbreath RW, Andreini H, Taubenslag W, Curtis R, et al. (March 2010). "Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting". Prostate Cancer and Prostatic Diseases. 13 (1): 71–7. doi:10.1038/pcan.2009.42. PMC 2834351. PMID 19786982.
75. Toktas G, Demiray M, Erkan E, Kocaaslan R, Yucetas U, Unluer SE. The effect of antibiotherapy on prostate-specific antigen levels and prostate biopsy results in patients with levels 2.5 to 10 ng/mL. J Endourol. 2013 Aug;27(8):1061-7. [PMC free article] [PubMed]
76. Tosoian JJ, Singhal U, Davenport MS, Wei JT, Montgomery JS, George AK, Salami SS, Mukundi SG, Siddiqui J, Kunju LP, Tooke BP, Ryder CY, Dugan SP, Chopra Z, Botbyl R, Feng Y, Sessine MS, Eyrich NW, Ross AE, Trock BJ, Tomlins SA, Palapattu GS, Chinnaiyan AM, Niknafs YS, Morgan TM. Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. Urology. 2022 Jun;164:184-190.
77. US Preventive Services Task Force. Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, Doubeni CA, Ebell M, Epling JW, Kemper AR, Krist AH, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Siu AL, Tseng CW. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 May 08;319(18):1901-1913.
78. Vickman RE, Franco OE, Moline DC, VanderGriend DJ, Thumbikat P, Hayward SW. The role of the androgen receptor in prostate development and benign prostatic hyperplasia. Asian J Urol. 2020;7:191-202.
79. Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Konety BR, Miner M, Moses K, Nissenberg MG, Pinto PA, Salami SS, Souter L, Thompson IM, Lin DW. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023 Jul;210(1):46-53.
80. Wilson RL, Taaffe DR, Newton RU, Hart NH, Lyons-Wall P, Galvão DA. Obesity and prostate cancer: A narrative review. Crit Rev Oncol Hematol. 2022;169:103543.
81. Woo S, Suh CH, Kim SY, Cho JY, Kim SH, Moon MH. Head-to-Head Comparison Between Biparametric and Multiparametric MRI for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2018;211(5):W226–w41.
82. Yaghi MD, Kehinde EO (2015). "Oral antibiotics in trans-rectal prostate biopsy and its efficacy to reduce infectious complications: Systematic review". Urology Annals. 7 (4): 41727. doi:10.4103/09747796.164860. PMC 4660689. PMID 26538868.
83. Yoo S, Pettersson A, Jordahl KM, Lis RT, Lindstrom S, Meisner A, et al. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2: ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014;23:2027-31.
84. Yu X, Liu R, Gao W, Wang X, Zhang Y. Single-cell omics traces the heterogeneity of prostate cancer cells and the tumor microenvironment. Cell Mol Biol Lett. 2023;28(1):38.
85. Zhang Y, Wang D, Peng M, Tang L, Ouyang J, Xiong F, et al. Single-cell RNA sequencing in cancer research. J Exp Clin Cancer Res. 2021; 40(1):81.
86. Zheng B, Fang L. Spatially resolved transcriptomics provide a new method for cancer research. J Exp Clin Cancer Res. 2022; 41(1):179.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 VIDYA - A JOURNAL OF GUJARAT UNIVERSITY
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
